Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Translational Lung Cancer Research|November 19, 2020
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancerIlaria Attili, Laura Bonanno, Niki Karachaliou, et al.
Frontiers in Oncology|July 15, 2021
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated CenterGiulia Pasello, Jessica Menis, Sara Pilotto, et al.
Tumori|February 19, 2024
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% FundLuigi Cerbone, Sara Delfanti, Stefania Crivellari, et al.
The Oncologist|May 31, 2022
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER StudyMartina Lorenzi, Alessandra Ferro, Fabiana Cecere, et al.
The Lancet. Oncology|September 9, 2021
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trialCarmine Pinto, Paolo Andrea Zucali, Maria Pagano, et al.
Translational Lung Cancer Research|August 9, 2024
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centersMariaenrica Tinè, Federica Pezzuto, Manuela Orlandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2017
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based ChemotherapyPaolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri, et al.
The Oncologist|March 9, 2019
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for <i>EGFR</i>-Positive Non-Small Cell Lung Cancer (MOST Study)Giulia Pasello, Giovanni Vicario, Fable Zustovich, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Translational Lung Cancer Research|November 19, 2020
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancerIlaria Attili, Laura Bonanno, Niki Karachaliou, et al.
Frontiers in Oncology|July 15, 2021
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated CenterGiulia Pasello, Jessica Menis, Sara Pilotto, et al.
Tumori|February 19, 2024
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% FundLuigi Cerbone, Sara Delfanti, Stefania Crivellari, et al.
The Oncologist|May 31, 2022
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER StudyMartina Lorenzi, Alessandra Ferro, Fabiana Cecere, et al.
The Lancet. Oncology|September 9, 2021
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trialCarmine Pinto, Paolo Andrea Zucali, Maria Pagano, et al.
Translational Lung Cancer Research|August 9, 2024
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centersMariaenrica Tinè, Federica Pezzuto, Manuela Orlandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2017
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based ChemotherapyPaolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri, et al.
The Oncologist|March 9, 2019
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for <i>EGFR</i>-Positive Non-Small Cell Lung Cancer (MOST Study)Giulia Pasello, Giovanni Vicario, Fable Zustovich, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Pageof 17